Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma

Leukemia. 2014 Mar;28(3):708-9. doi: 10.1038/leu.2013.332. Epub 2013 Nov 12.

Authors

S Dietrich¹, J Weidle¹, M Rieger¹, J Meissner¹, A Radujkovic¹, A D Ho¹, P Dreger¹, M Witzens-Harig¹

Affiliation

¹ Department of Hematology, University Hospital of Heidelberg, Heidelberg, Germany.

PMID: 24217198
DOI: 10.1038/leu.2013.332

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Antibodies, Monoclonal, Murine-Derived / therapeutic use*
Antineoplastic Agents / therapeutic use*
Disease-Free Survival
Female
Humans
Lymphoma, Mantle-Cell / drug therapy*
Lymphoma, Mantle-Cell / pathology
Male
Middle Aged
Rituximab
Stem Cell Transplantation*

Substances

Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents
Rituximab